Systemic Sclerosis
Systemic sclerosis is an autoimmune condition characterised by thickening and hardening of the skin (sclerosis) and other connective tissues. There are 3 distinct patterns of systemic sclerosis, including:
- Limited cutaneous SS
- Diffuse cutaneous SS
- Scleroderma
90% of patients with any form are ANA positive.
Limited cutaneous systemic sclerosis
Clinical Features
- Typically women aged 30-50 years of age
- Sclerosis affects the face & distal limbs
- Raynaud’s phenomenon is common
- Used to be referred to as CREST syndrome. Features of LCSS therefore include: Calcinosis, Raynaud’s, Esophageal dysfunction, Sclerodactyly, Telangiectasia
Antibody
- Anti-centromere antibodies, ANA
Diffuse cutaneous systemic sclerosis
Clinical Features
- Typically women aged 30-50 years of age
- Sclerosis affects the trunk & proximal limbs
Complications
- Interstitial lung disease (up to 8/10 patients) - SSc-ILD (Scleroderma-related ILD) - pulmonary fibrosis with progressive respiratory failure
- Pulmonary hypertension
- Hypertension, CKD
Antibody
- SCL-70 antibodies, ANA
Scleroderma
Clinical Features
- Hardened, thickened areas of skin. Tightening of the skin gives a 'shiny' appearance.
- Plaque morphoea - oval patches of discoloured, hardened skin which might be shiny
- Linear morphoea: thickened lines of skin along the arms and legs
- No organ involvement
Sjogren’s Syndrome
Pathophysiology
- Autoimmune mediated destruction of exocrine glands
- Classification
- Primary Sjogren’s
- Secondary Sjogren’s - rheumatoid arthritis, connective tissue disease
Clinical Features
- Epidemiology: Typically affects middle aged women
- Generalised features:
- Fatigue
- Diffuse, generalised joint pain
- Exocrine dysfunction results in:
- Keratoconjunctivitis Sicca - dry eyes - a foreign body, gritty sensation and light sensitivity
- Dry mouth - xerostomia - difficulty chewing, swallowing or talking.
- Increased risk of oral candidiasis
- Parotitis - facial swelling
- Vaginal dryness
- Photosensitive rashes
Complications
- Lymphoid malignancy ( x 50 risk)
Investigations
Antibodies
- Rheumatoid factor - 50% positive
- ANA - 70% positive
- ANTI-RO (SSA) - 70% Primary SS
- Anti-La (SSB) - 30%
Investigations
- Schirmer’s test - reduced tear film (<5mm after 5 minutes)
- Labial (lip) salivary gland biopsy - histology -l focal lymphocytic infiltration
- Anti-Ro/La positive
Management
- Dry eyes and mouth - pilocarpine, artificial tears
Dermatomyositis
Dermatomyositis is an inflammatory condition resulting in symmetrical proximal muscle weakness and skin lesions.
Causes
- Underlying malignancy in 25% of patients - ovarian, breast, lung
- Idiopathic
Clinical features
Cutaneous features - 'Dermato...'
- Heliotrope periorbital rash - redish/purple rash on eyelids
- Red macular rash affecting back and shoulders
- Mechanics hands – Gottron’s red papules on extensor surfaces - often overlying the knuckles and PIP/DIP joints
- Rashes are photosensitive
‘Myositis..’
- Symmetrical, proximal weakness +/- tenderness
- Difficult climbing stairs, getting up from chair, holding up a cup of tea or brushing hair etc.
General symptoms
- Fatigue
- Weight loss
- Night sweats
Other features: ILD causing shortness of breath, Raynaud’s phenomenon
Investigations
Bloods
- Raised CK due to myositis
- ANA positive (80%)
- Antibodies:
- Anti-MI-2 Antibodies
- Anti-SRP antibodies
- (Anti-Jo 1 antibodies - more associated with polymyositis)
Management
- Steroids - Prednisolone
- Patients should be screened for malignancy
Polymyositis
- A variant of dermatomyositis without skin manifestations
- Antibodies: Anti-JO1 (vs histidine tRNA ligase)
Mixed Connective Tissue Disease / Sharp's Syndrome
Pathophysiology
- A multisystem autoimmune disease with mixed features of SLE, systemic sclerosis and myositis.
Clinical Features
- Myalgia
- Shortness of breath due to pulmonary hypertension
- Polyarthralgia
- Raynaud's phenomenon
- Dactylitis "sausage fingers"
- Rash
- Oesophageal dysfunction / swallowing difficulties
- Renal/CNS disease is unlikely
Antibodies
- Anti-U1 ribonucleoprotein antibodies (Anti-RNP)
Management
- DMARDs
Relapsing Polychondritis
Pathophysiology
- Episodic inflammation of cartilage, particularly of the ears, nose, joints
Clinical Features
- Ears - Auricular chondritis, hearing loss, vertigo
- Nose - nasal chondritis - saddle nose
- Respiratory tract - hoarse voice, aphonia, wheeze
- Joints - arthralgia
Management
- Steroids can be used to induce remission
- Maintenance - DMARDs
Familial Mediterranean Fever
Pathophysiology
- An autosomal recessive disease resulting in recurrent episodes of acute polyserositis
Epidemiology
- Increased prevalence in patients of Turkish, Armenian, Arabic descent
Clinical features
- Patients have 'attacks' lasting 1-3 days with symptoms including:
- Fever
- Pleurisy
- Abdominal pain, peritonitis
- Pericarditis
- Arthritis
- Erysipeloid rash on the lower limbs
Management
- 1st line - colchicine
Pseudoxanthoma Elasticum
Pathophysiology
- An autosomal recessive disease caused by calcium deposition and mineralization of the elastic fibres of connective tissues around the body.
Clinical Features
- Retinal angioid streaks - red bands radiating from the disc.
- 'Plucked chicken skin appearance'
- Small yellow papules in a liner pattern, in groups forming plaques
- Loss of elastic tissue and saggy looking skin in neck, axilla etc.
- Cardiovascular complications:
- Intermittent claudication is a common early sign of arterial disease
- Ischaemic heart disease
- MV valve prolapse
- Gastrointestinal bleeding - melaena/frank bleeding/occult in stool
Adult-onset Still’s Disease
Pathophysiology
- A systemic autoimmune disease
Clinical features
A triad of:
- Fever
- Joint pain - especially the knees, wrists and ankles
- Maculopapular salmon rash
- Other - lymphadenopathy, sore throat, hepatosplenomegaly, myalgia, pericarditis.
Investigations
- No single diagnostic test - Ferritin, ESR and CRP elevated
- Autoantibodies: Rheumatoid factor and ANA are negative
Management
- 1st Line: NSAIDs and corticosteroids
- NSAIDs for symptomatic control
- Once diagnosis is confirmed patients can be treated with steroids
- Long term: DMARDs - Methotrexate
- Alternatives: ciclosporin, leflunomide, azathioprine, MMF, cyclophosphamide
- Alternative: If failure of 2 DMARDs, Anakinra (IL-1 receptor antagonist) is recommended by NICE